Recent progress in oligonucleotide therapeutics: antisense to aptamers (Q47563314)

4 February 2018

title

Recent progress in oligonucleotide therapeutics: antisense to aptamers (English)

1 reference

4 February 2018

author name string

Douglas W Leaman

series ordinal

1

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 September 2008

1 reference

4 February 2018

Expert Opinion on Drug Discovery

published in

1 reference

4 February 2018

volume

3

1 reference

4 February 2018

issue

9

1 reference

4 February 2018

page(s)

997-1009

1 reference

4 February 2018

RNAi therapeutics: principles, prospects and challenges

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

An overview of progress in antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Progress in antisense technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Progress in the development of nucleic acid therapeutics for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

An antisense oligonucleotide primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Novel antisense and peptide nucleic acid strategies for controlling gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

RNA interference against viruses: strike and counterstrike

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

The experimental use of antisense oligonucleotides: a guide for the perplexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Approaches for the sequence-specific knockdown of mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

DNA-based therapeutics and DNA delivery systems: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

2'-Modified oligonucleotides for antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antisense apolipoprotein B therapy: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Apolipoprotein polymorphisms and familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antisense- and RNA interference-based therapeutic strategies in allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Design of antisense oligonucleotides stabilized by locked nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

The peptide nucleic acids: a new way for chromosomal investigation on isolated cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

RNAi therapeutics: how likely, how soon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

siRNA function in RNAi: a chemical modification analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

2-5A antisense treatment of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Inhibition of respiratory viruses by nasally administered siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Antibody-targeted liposomes in cancer therapy and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Pegylation: engineering improved pharmaceuticals for enhanced therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Non-viral gene transfer therapy for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Viral vectors for gene transfer: a review of their use in the treatment of human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Intracellular trafficking and transgene expression of viral and non-viral gene vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Virus-based gene delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Gene therapy progress and prospects: adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Micellar nanocarriers: pharmaceutical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Liver-directed gene transfer: a linear polyethlenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Polyethyleneimine-mediated transfection to improve antisense activity of 3'-capped phosphodiester oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Cell-penetrating-peptide-based delivery of oligonucleotides: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Chances and pitfalls of cell penetrating peptides for cellular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Cell-penetrating peptides for drug delivery across membrane barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Cell penetrating peptide conjugates of steric block oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Aptamers: an emerging class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Pharmacokinetics and biodistribution of novel aptamer compositions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Toll-Like receptors (TLRs) and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Interferons at age 50: past, current and future impact on biomedicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

'Toll' gates for future immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

Activation of the interferon system by short-interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.9.997

21 January 2018

Identifiers

DOI

10.1517/17460441.3.9.997

1 reference

4 February 2018

release_x4jle7qtjbhg7pqgl7ojaljjni

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x4jle7qtjbhg7pqgl7ojaljjni

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

4 February 2018